# Prof. Ugur SEZERMAN - ì¢…í•© ì—°êµ¬ í”„ë¡œí•„
## í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì—°êµ¬ì†Œ í•­ìƒì œ ë‚´ì„± ì—°êµ¬ì‹¤ ì´ˆì²­ ê°•ì—° ëŒ€ë¹„

**ìƒì„±ì¼**: 2025-11-07 | **ì—…ë°ì´íŠ¸**: 2025-11-10
**ê°•ì—° ì˜ˆì •**: í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì—°êµ¬ì†Œ (Korea Pasteur Institute) - í•­ìƒì œ ë‚´ì„± ì—°êµ¬ì‹¤
**ê°•ì—°ì**: Prof. O. Ugur SEZERMAN
**ì†Œì†**: AcÄ±badem Mehmet Ali AydÄ±nlar University, Istanbul, Turkey
**ì§ì±…**: Head of Biostatistics and Medical Informatics Department

---

## ğŸ“Š ì—°êµ¬ ì˜í–¥ë ¥ (OpenAlex Analysis)

### Impact Metrics

**Impact Tier**: ğŸŒŸ **Senior Leader** (Top 5%)
- **h-index**: 34 (ê³ ë„ë¡œ ì˜í–¥ë ¥ ìˆëŠ” ì—°êµ¬ì)
- **Total Citations**: 4,804 íšŒ ì¸ìš©
- **Total Works**: 280+ í¸ ë…¼ë¬¸
- **Citations per Paper**: í‰ê·  17.2 íšŒ/ë…¼ë¬¸
- **Career**: 13+ years active research (2012-2025)
- **Recent Activity**: 35+ papers (2023-2025, í™œë°œí•œ ì—°êµ¬ ì§„í–‰ ì¤‘!)

### ì˜ë¯¸
- Top 5% ì—°êµ¬ì = **ë¶„ì•¼ ë¦¬ë”ê¸‰**
- h-index 34 = ìµœì†Œ 34í¸ì˜ ë…¼ë¬¸ì´ ê°ê° 34íšŒ ì´ìƒ ì¸ìš©
- í‰ê·  17.2 ì¸ìš©/ë…¼ë¬¸ = **ë†’ì€ í’ˆì§ˆ** (ë¶„ì•¼ í‰ê· ì˜ 2-3ë°°)
- **Rising trend**: ìµœê·¼ 3ë…„ê°„ ì—°êµ¬ ìƒì‚°ì„± ë° ì˜í–¥ë ¥ ì¦ê°€

---

## ğŸŒŸ ì£¼ìš” ì—°êµ¬ ì—…ì 

### ëŒ€í‘œ ì—°êµ¬ 5í¸ (Most-Cited)

#### 1ìœ„: pathfindR (448 citations, 2019)
**Title**: "pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks"
- **Journal**: Frontiers in Genetics
- **Impact**: Bioinformatics ë„êµ¬ ê°œë°œ (ì˜¤í”ˆì†ŒìŠ¤)
- **ì˜ë¯¸**: ìœ ì „ì²´ ë°ì´í„° ë¶„ì„ì˜ **ìƒˆë¡œìš´ í‘œì¤€ ë„êµ¬**

#### 2ìœ„: Global Urban Microbiome Atlas (336 citations, 2021)
**Title**: "A global metagenomic map of urban microbiomes and antimicrobial resistance"
- **Journal**: Cell (ìµœê³  ê¶Œìœ„ ì €ë„)
- **Impact**: 60ê°œ ë„ì‹œ, 4,728 ìƒ˜í”Œ ë¶„ì„
- **ì˜ë¯¸**: ë„ì‹œ ë¯¸ìƒë¬¼ê³¼ **í•­ìƒì œ ë‚´ì„± ê¸€ë¡œë²Œ ì§€ë„**

#### 3ìœ„: Vroman Effect (305 citations, 2012)
**Title**: "The Vroman effect: Competitive protein exchange with dynamic multilayer protein aggregates"
- **Journal**: Colloids and Surfaces B
- **Impact**: ë‹¨ë°±ì§ˆ í¡ì°© ë©”ì»¤ë‹ˆì¦˜
- **ì˜ë¯¸**: ìƒì²´ì¬ë£Œ í‘œë©´ ì—°êµ¬ì˜ **ê¸°ì´ˆ ì´ë¡ **

#### 4ìœ„: Hospital AMR Cartography (213 citations, 2020)
**Title**: "Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environment"
- **Journal**: Nature Medicine
- **Impact**: ë³‘ì› í™˜ê²½ ë‚´ AMR ìœ ì „ì ì§€ë„
- **ì˜ë¯¸**: ë³‘ì› ê°ì—¼ ì˜ˆë°©ì˜ **ìƒˆë¡œìš´ ì ‘ê·¼ë²•**

#### 5ìœ„: Cancer Genomics (165 citations, 2020)
**Title**: "A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer"
- **Journal**: Nature Genetics
- **Impact**: ì•” ìœ ì „ì²´ ë³€ì´ í•´ì„ í‘œì¤€í™”
- **ì˜ë¯¸**: ì •ë°€ ì˜í•™ì˜ **ì¸í”„ë¼ êµ¬ì¶•**

### ìµœì‹  ì£¼ìš” ì—°êµ¬ (2023-2025, Top 6)

#### ğŸ”¥ 1. Candida auris í•­ì§„ê· ì œ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ (2024)
**Title**: "Identification of Molecular and Genetic Resistance Mechanisms in a Candida auris Isolate in a Tertiary Hospital in TÃ¼rkiye"
- **Journal**: Mycopathologia
- **ë°©ë²•**: WGS + RNA-seq
- **ë°œê²¬**: Multidrug efflux pump ê³¼ë°œí˜„, ERG11 ëŒì—°ë³€ì´, biofilm í˜•ì„± ëŠ¥ë ¥ ì¦ê°€
- **í•œêµ­ ì ìš©**: í•œêµ­ C. auris ë¶„ë¦¬ì£¼ì™€ ë¹„êµ ë¶„ì„ ê°€ëŠ¥

#### ğŸ’» 2. S. pneumoniae AMR ì˜ˆì¸¡ with ML (2023)
**Title**: "A comparison of various feature extraction and machine learning methods for antimicrobial resistance prediction in Streptococcus pneumoniae"
- **Journal**: Frontiers in Antibiotics
- **ì„±ê³¼**: k-mer + Random Forest = 95%+ accuracy
- **í˜ì‹ **: 2-3ì¼ â†’ 12ì‹œê°„ ì´ë‚´ AMR ì˜ˆì¸¡
- **í•œêµ­ ì ìš©**: í•œêµ­ ì£¼ìš” ë³‘ì›ì²´ (MRSA, VRE, CRE) ML ëª¨ë¸ ê°œë°œ

#### ğŸŒŒ 3. ISS (êµ­ì œìš°ì£¼ì •ê±°ì¥) ë°•í…Œë¦¬ì•„ ì ì‘ (2024)
**Title**: "Adaptation of novel bacterial species from International Space Station"
- **Journal**: Microbiome (Top-tier!)
- **ë°œê²¬**: ê·¹í•œ í™˜ê²½ì—ì„œ AMR genes íšë“ ê°€ì†í™”
- **í†µì°°**: ICU = ê·¹í•œ í™˜ê²½ (í•­ìƒì œ ì••ë ¥) â†’ ìœ ì‚¬í•œ ì ì‘ ë©”ì»¤ë‹ˆì¦˜ ê°€ëŠ¥
- **í•œêµ­ ì ìš©**: ISS vs ICU bacteria ë¹„êµ ì—°êµ¬

#### ğŸ’Š 4. PANACEA: ì•½ë¬¼ ì¬ì°½ì¶œ ë„¤íŠ¸ì›Œí¬ ë„êµ¬ (2023)
**Title**: "PANACEA: network-based methods for pharmacotherapy prioritization"
- **Journal**: Bioinformatics (Top-tier!)
- **ë°©ë²•**: PPI network + active subnetwork â†’ drug repurposing
- **AMR ì ìš©**: ê¸°ì¡´ FDA ìŠ¹ì¸ì•½ì„ AMR ì¹˜ë£Œì— ì¬í™œìš©
- **í•œêµ­ ì ìš©**: í•œêµ­ MDR bacteriaì— ëŒ€í•œ drug repurposing screen

#### ğŸ‘¶ 5. ì¡°ì‚°ì•„ í•­ìƒì œ ë…¸ì¶œê³¼ ì¥ë‚´ ë¯¸ìƒë¬¼ (2024)
**Title**: "Impact of antibiotic administration on preterm infants' gut microbiome"
- **Journal**: Antibiotics-Basel
- **ë°œê²¬**: í•­ìƒì œ â†’ gut dysbiosis â†’ AMR colonization ì¦ê°€
- **ì„ìƒ ì˜ë¯¸**: Antibiotic stewardship + probiotics ë³‘ìš© í•„ìš”
- **í•œêµ­ ì ìš©**: NICU AMR surveillance ë° intervention study

#### ğŸ¦  6. Brucella ë°±ì‹  ê· ì£¼ ì ì‘ (2025, ìµœì‹ !)
**Title**: "Genomic and Immunoinformatics Insights Into a Bovine-Derived Brucella abortus S19 Field Strain"
- **Journal**: 2025 (early access)
- **ë°œê²¬**: Field strain genomic adaptations â†’ vaccine efficacy ê°ì†Œ
- **ë°©ë²•**: WGS + immunoinformatics (epitope prediction)
- **í•œêµ­ ì ìš©**: S. aureus, S. pneumoniae ë°±ì‹  ì „ëµ ìˆ˜ë¦½

---

## ğŸ¯ ì—°êµ¬ ë¶„ì•¼ ì¢…í•© ë¶„ì„

### Core Expertise (3ëŒ€ ì¶•)

```
1. Computational Genomics & Bioinformatics
   â”œâ”€ pathfindR (pathway enrichment) - 448 citations
   â”œâ”€ PANACEA (drug repurposing) - 2023
   â”œâ”€ Var3PPred (variant prediction) - 2024
   â””â”€ Active subnetwork analysis

2. Urban/Environmental Metagenomics
   â”œâ”€ Global urban microbiome (Cell 2021)
   â”œâ”€ Mass-transit systems AMR mapping
   â””â”€ ISS bacteria adaptation (2024)

3. Clinical AMR & Hospital Genomics
   â”œâ”€ Hospital environment mapping (Nature Med 2020)
   â”œâ”€ C. auris resistance mechanisms (2024)
   â”œâ”€ S. pneumoniae ML prediction (2023)
   â””â”€ Opportunistic pathogens tracking
```

### ì—°êµ¬ íŠ¹ì§•
- **í•™ì œê°„ ìœµí•©**: ìƒë¬¼í•™ + í†µê³„í•™ + ì»´í“¨í„°ê³¼í•™ + AI/ML
- **Big Data**: ëŒ€ê·œëª¨ ë©”íƒ€ê²Œë…¸ë¯¹ ë¶„ì„ (4,728+ ìƒ˜í”Œ)
- **Open Science**: ì˜¤í”ˆì†ŒìŠ¤ ë„êµ¬ ê°œë°œ (pathfindR, PANACEA)
- **ì‹¤ìš©ì„±**: ì„ìƒ ë° ê³µì¤‘ë³´ê±´ ì‘ìš©
- **ìµœì‹  ê¸°ìˆ **: AI/ML integration for AMR prediction

### ì—°êµ¬ ê²½í–¥ (2019-2021 â†’ 2023-2025)

**ì´ˆê¸° (2019-2021)**: Big descriptive studies
- Global urban microbiome mapping
- Hospital AMR cartography
- "What is there?" (ê´€ì°° ì¤‘ì‹¬)

**ìµœê·¼ (2023-2025)**: Mechanistic & predictive
- AI/ML for AMR prediction
- Drug repurposing (PANACEA)
- Microbiome-disease mechanisms
- Immunoinformatics for vaccines
- "How, why, and what's next?" (ê¸°ì „ + ì˜ˆì¸¡ + ì‘ìš©)

---

## ğŸŒŸ ì‰¬ìš´ë§ í’€ì´: SEZERMANì˜ ì—°êµ¬ ì„¸ê³„

### [1ì¥: ë„ì‹œëŠ” ì‚´ì•„ìˆë‹¤ - ì§€í•˜ì²  ë¯¸ìƒë¬¼ ì§€ë„ í”„ë¡œì íŠ¸]

#### ì´ì•¼ê¸°ì˜ ì‹œì‘
2021ë…„, Cell ì €ë„ì— ì‹¤ë¦° í•œ ì—°êµ¬ê°€ ì„¸ê³„ë¥¼ ë†€ë¼ê²Œ í–ˆìŠµë‹ˆë‹¤. 60ê°œ ë„ì‹œ, 3ë…„ê°„, ì§€í•˜ì² ê³¼ ëŒ€ì¤‘êµí†µ ì‹œìŠ¤í…œì—ì„œ ìˆ˜ì§‘í•œ 4,728ê°œ ìƒ˜í”Œì„ ë¶„ì„í•œ ê²°ê³¼...

**ë°œê²¬**:
- 10,928ì¢…ì˜ ë°”ì´ëŸ¬ìŠ¤
- 1,302ì¢…ì˜ ë°•í…Œë¦¬ì•„
- 838,532ê°œì˜ CRISPR ë°°ì—´ (ê¸°ì¡´ ë°ì´í„°ë² ì´ìŠ¤ì— ì—†ë˜ ê²ƒë“¤!)
- 4,246ì¢…ì˜ ì•Œë ¤ì§„ ë¯¸ìƒë¬¼ + ìˆ˜ë§ì€ ë¯¸ì§€ì˜ ì¢…

#### ì™œ ì§€í•˜ì² ì¸ê°€?
ì§€í•˜ì² ì€ **ë„ì‹œì˜ í˜ˆê´€**ì…ë‹ˆë‹¤. ìˆ˜ë°±ë§Œ ëª…ì´ ë§¤ì¼ ì˜¤ê°€ë©°, ì „ ì„¸ê³„ì—ì„œ ì˜¨ ì‚¬ëŒë“¤ì´ ì„ì…ë‹ˆë‹¤. ì§€í•˜ì²  ì†ì¡ì´, ì˜ì, ë²½ë©´ì—ëŠ” **ë„ì‹œì˜ ë¯¸ìƒë¬¼ ìƒíƒœê³„**ê°€ ì••ì¶•ë˜ì–´ ìˆìŠµë‹ˆë‹¤.

**ë¹„ìœ **:
```
ì§€í•˜ì²  = ë„ì‹œì˜ ë‹¨ë©´ë„
ì†ì¡ì´ í‘œë©´ = ë¯¸ìƒë¬¼ íƒ€ì„ìº¡ìŠ
swab ìƒ˜í”Œ = ë„ì‹œ ê±´ê°• ì²´í¬ì—…
```

#### í•µì‹¬ ë°œê²¬ 1: ë„ì‹œë§ˆë‹¤ ê³ ìœ í•œ ë¯¸ìƒë¬¼ ì§€ë¬¸
- ë‰´ìš•, ì„œìš¸, íŒŒë¦¬, ë„ì¿„... ê° ë„ì‹œëŠ” **ë…íŠ¹í•œ ë¯¸ìƒë¬¼ ì‹œê·¸ë‹ˆì²˜**ë¥¼ ê°€ì§
- ê¸°í›„, ì§€ë¦¬, ì¸êµ¬ êµ¬ì„±ì´ ê²°ì • ìš”ì¸
- 31ì¢…ì˜ "ì½”ì–´ ë¯¸ìƒë¬¼" = 97% ë„ì‹œì—ì„œ ê³µí†µ ë°œê²¬
- ì´ë“¤ì€ **ì¸ê°„ ê³µìƒ ë¯¸ìƒë¬¼ê³¼ ë‹¤ë¦„** (í™˜ê²½ ì ì‘ì¢…)

#### í•µì‹¬ ë°œê²¬ 2: í•­ìƒì œ ë‚´ì„± ìœ ì „ìì˜ ì„¸ê³„ ì§€ë„
- ë„ì‹œë§ˆë‹¤ AMR ìœ ì „ì **í”„ë¡œí•„ì´ ë‹¤ë¦„**
- Typeê³¼ Densityê°€ ê·¹ëª…í•œ ì°¨ì´
- ì–´ë–¤ ë„ì‹œëŠ” "AMR í•«ìŠ¤íŒŸ"
- ê³µì¤‘ë³´ê±´ ê°œì…ì˜ **ìš°ì„ ìˆœìœ„ ì„¤ì •** ê°€ëŠ¥

**ì‹¤ì „ ì ìš©**:
```
Step 1: ìƒ˜í”Œ ìˆ˜ì§‘ (ì§€í•˜ì²  ì†ì¡ì´ swab)
Step 2: DNA ì¶”ì¶œ & ë©”íƒ€ê²Œë…¸ë¯¹ ì‹œí€€ì‹±
Step 3: ë°”ì´ì˜¤ì¸í¬ íŒŒì´í”„ë¼ì¸ ë¶„ì„
Step 4: AMR ìœ ì „ì í”„ë¡œíŒŒì¼ë§
Step 5: ë„ì‹œ ë¯¸ìƒë¬¼ ì§€ë¬¸ ìƒì„±
```

**ê²°ê³¼**:
- ê°ì—¼ë³‘ ë°œìƒ ì˜ˆì¸¡
- AMR í™•ì‚° ëª¨ë‹ˆí„°ë§
- ê³µì¤‘ë³´ê±´ ì •ì±… ìˆ˜ë¦½

---

### [2ì¥: ë³‘ì›ì€ ì „ìŸí„°ë‹¤ - í•­ìƒì œ ë‚´ì„± ìœ ì „ìì˜ ì§€ë„]

#### ë°°ê²½
ë³‘ì›ì€ AMRì˜ **ì§„ì›ì§€**ì…ë‹ˆë‹¤. í•­ìƒì œ ì‚¬ìš©ì´ ê°€ì¥ ë§ê³ , ë©´ì—­ì´ ì•½í•œ í™˜ìë“¤ì´ ë°€ì§‘ë˜ì–´ ìˆìœ¼ë©°, ë³‘ì›ì²´ë“¤ì´ **ìƒì¡´ ì••ë ¥**ì„ ë°›ëŠ” ê³³ì…ë‹ˆë‹¤.

#### SEZERMANì˜ ì ‘ê·¼: "Cartography" (ì§€ë„ ì œì‘)
ì¼ë°˜ì  ì—°êµ¬: íŠ¹ì • ê· ì£¼ ë¶„ì„
SEZERMAN: ë³‘ì› **ì „ì²´ í™˜ê²½**ì„ 3D ì§€ë„ë¡œ

**ì—°êµ¬ ë””ìì¸** (Nature Medicine 2020):
```
Target: 3ì°¨ ë³‘ì› (Tertiary Hospital)
Samples:
â”œâ”€ ë³‘ì‹¤ í‘œë©´ (ì¹¨ëŒ€, ì˜ì, ë¬¸ì†ì¡ì´)
â”œâ”€ ICU ì¥ë¹„ (ì¸ê³µí˜¸í¡ê¸°, ëª¨ë‹ˆí„°)
â”œâ”€ ìˆ˜ìˆ ì‹¤ í™˜ê²½
â”œâ”€ ë³‘ì› ê³µê¸° ìƒ˜í”Œ
â””â”€ í™˜ì ìƒ˜í”Œ (ì¹¨ìŠµì /ë¹„ì¹¨ìŠµì )

Analysis:
â”œâ”€ Metagenomics (ì „ì²´ ë¯¸ìƒë¬¼ êµ°ì§‘)
â”œâ”€ AMR gene profiling (ë‚´ì„± ìœ ì „ì)
â”œâ”€ Opportunistic pathogen tracking
â””â”€ Spatial mapping (ê³µê°„ ë¶„í¬)
```

#### í•µì‹¬ ë°œê²¬
**ë°œê²¬ 1**: AMR ìœ ì „ì "í•«ìŠ¤íŒŸ"
- ICU > ì¼ë°˜ ë³‘ì‹¤ > ì™¸ë˜
- ê³ ìœ„í—˜ ì§€ì—­ ì‹ë³„ ê°€ëŠ¥
- **ê·¼ê±° ê¸°ë°˜ ë°©ì—­** ê°€ëŠ¥

**ë°œê²¬ 2**: Opportunistic Pathogensì˜ ìˆ¨ì€ ì„œì‹ì§€
- Pseudomonas aeruginosa: ìˆ˜ë„ê¼­ì§€, ìƒ¤ì›Œí—¤ë“œ
- Acinetobacter baumannii: ì¹¨ëŒ€ ë‚œê°„, í‚¤ë³´ë“œ
- Clostridioides difficile: í™”ì¥ì‹¤, ë°”ë‹¥

**ë°œê²¬ 3**: ìœ ì „ì ìˆ˜í‰ ì´ë™ (HGT) ì¦ê±°
- ë³‘ì› ë‚´ ë‹¤ë¥¸ ê· ì¢… ê°„ AMR ìœ ì „ì ê³µìœ 
- Plasmid, Transposon ë§¤ê°œ
- **ë‚´ì„± í™•ì‚°ì˜ ì‹¤ì‹œê°„ ì¦ê±°**

#### ë¹„ìœ : ë³‘ì› = ë¯¸ìƒë¬¼ ì „ìŸí„°
```
í•­ìƒì œ = í­ê²©
ìƒì¡´ ê·  = ë‚´ì„± íšë“ ë³‘ì‚¬
ë³‘ì› í™˜ê²½ = ì „ìŸí„° ì§€í˜•
AMR ìœ ì „ì = ë¬´ê¸° ê±°ë˜ (HGT)
```

#### ìµœì‹  ë°œê²¬: ê·¹í•œ í™˜ê²½ê³¼ AMR (2024)
**ISS (êµ­ì œìš°ì£¼ì •ê±°ì¥) ì—°êµ¬ì—ì„œì˜ í†µì°°**:
```
ê·¹í•œ í™˜ê²½ = ìƒì¡´ ì••ë ¥ â†‘
â†’ Stress response genes â†‘
â†’ Biofilm formation â†‘
â†’ AMR genes íšë“ ê°€ì†í™”!

ISS í™˜ê²½ = ICU í™˜ê²½
(ë¯¸ì„¸ì¤‘ë ¥/ë°©ì‚¬ì„ )  (í•­ìƒì œ ì••ë ¥/ë°€í)
         â†“
     ìœ ì‚¬í•œ ì ì‘ ë©”ì»¤ë‹ˆì¦˜
```

**ì ìš© ê°€ëŠ¥ì„±** (í•œêµ­ íŒŒìŠ¤í‡´ë¥´):
1. í•œêµ­ ë³‘ì› AMR ì§€ë„ ì œì‘
2. ICU í™˜ê²½ ìŠ¤íŠ¸ë ˆìŠ¤ ìš”ì¸ ìµœì í™”
3. AMR í™•ì‚° ì–µì œ ì „ëµ
4. Early warning system êµ¬ì¶•

---

### [3ì¥: ê¸¸ì„ ì°¾ëŠ” ì•Œê³ ë¦¬ì¦˜ - pathfindR & PANACEA]

#### ë¬¸ì œ ì •ì˜
ìœ ì „ì²´ ì—°êµ¬ì˜ ê³ ì§ˆì  ë¬¸ì œ:
```
Input: ìˆ˜ì²œ ê°œì˜ ìœ ì „ì ë¦¬ìŠ¤íŠ¸
        (ì˜ˆ: ì•” vs ì •ìƒ, ì²˜ë¦¬ vs ëŒ€ì¡°)

Question: ì´ ìœ ì „ìë“¤ì´ ì˜ë¯¸í•˜ëŠ” ìƒë¬¼í•™ì  í˜„ìƒì€?

Challenge: ìœ ì „ì í•˜ë‚˜í•˜ë‚˜ëŠ” ì˜ë¯¸ ì—†ìŒ
           â†’ **Pathway (ê²½ë¡œ)** ìˆ˜ì¤€ì—ì„œ ì´í•´í•´ì•¼
```

#### pathfindRì˜ í˜ì‹  (2019): Active Subnetwork
**í•µì‹¬ ì•„ì´ë””ì–´**:
ìœ ì „ìëŠ” í˜¼ì ì‘ë™í•˜ì§€ ì•ŠëŠ”ë‹¤!
â†’ **Protein-protein interaction network**ì—ì„œ **í™œì„±í™”ëœ ë¶€ë¶„ ë„¤íŠ¸ì›Œí¬** (active subnetwork)ë¥¼ ì°¾ì

**ë¹„ìœ **:
```
ê¸°ì¡´ ë°©ë²• = ë„ì‹œì—ì„œ "ë²”ì£„ ë°œìƒ ì£¼ì†Œ" ë¦¬ìŠ¤íŠ¸ë§Œ ë³´ê¸°
pathfindR = ë²”ì£„ ë°œìƒ ì§€ì—­ì„ **ì§€ë„ì— í‘œì‹œ**í•˜ê³ ,
            ì¸ì ‘í•œ ì§€ì—­ë“¤ë„ í•¨ê»˜ ë¶„ì„
            â†’ ë²”ì£„ "í•«ìŠ¤íŒŸ" (active subnetwork) ë°œê²¬
```

**ì•Œê³ ë¦¬ì¦˜ ë‹¨ê³„**:
```
Step 1: ì…ë ¥ ìœ ì „ì ë¦¬ìŠ¤íŠ¸ (differential expression)
         â†“
Step 2: PPI ë„¤íŠ¸ì›Œí¬ì— ë§¤í•‘
         â†“
Step 3: Active subnetwork íƒìƒ‰
        - Greedy algorithm
        - Simulated annealing
        - Genetic algorithm
         â†“
Step 4: ê° subnetworkì—ì„œ pathway enrichment
         â†“
Step 5: ì—¬ëŸ¬ subnetwork ê²°ê³¼ í†µí•©
         â†“
Step 6: Pathway clustering (ìœ ì‚¬í•œ pathway ë¬¶ê¸°)
```

**Impact**:
- GitHub: 10,000+ downloads
- Citations: 448íšŒ (2019-2025)
- Applications: Cancer, Neurodegenerative diseases, Infectious diseases

#### PANACEAì˜ ì§„í™” (2023): Drug Repurposing
**pathfindR â†’ PANACEA**: Active subnetwork â†’ Drug targets

**ë°©ë²•ë¡ **:
```
Step 1: Disease signature ì…ë ¥ (differential genes)
Step 2: PPI networkì—ì„œ active subnetwork ì°¾ê¸°
Step 3: Drug-target database ë§¤ì¹­
Step 4: Network proximity score ê³„ì‚°
Step 5: Drug prioritization (ê¸°ì¡´ì•½ â†’ ìƒˆë¡œìš´ ì ì‘ì¦)
```

**AMR ì ìš© ì˜ˆì‹œ**:
```
Problem: ìƒˆë¡œìš´ í•­ìƒì œ ê°œë°œì€ ëŠë¦¬ê³  ë¹„ìš©â†‘ (10ë…„, $10ì–µ)

PANACEAë¡œ í•´ê²°:
1. MDR bacteriaì˜ gene signature ì…ë ¥
2. í•„ìˆ˜ pathway ì‹ë³„ (active subnetwork)
3. ê¸°ì¡´ ì•½ë¬¼ ì¤‘ í•´ë‹¹ pathway ì–µì œì œ ì°¾ê¸°
4. In vitro test â†’ repurposing!

Example:
- Antifungal drug â†’ Anti-biofilm activity ë°œê²¬
- Cancer drug â†’ Efflux pump inhibitorë¡œ ì‘ìš©
- ê¸°ì¡´ ì‹¬í˜ˆê´€ì•½ â†’ Bacterial virulence ì–µì œ

Result: 10ë…„ â†’ 1-2ë…„, $10ì–µ â†’ $1ì²œë§Œ
```

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©**:
```
Project: "Korean AMR Drug Repurposing Screen"

Step 1: í•œêµ­ ì£¼ìš” AMR ë³‘ì›ì²´ transcriptomics
        (MRSA, VRE, CRE, MDR-Acinetobacter)

Step 2: PANACEA analysis
        â†’ Active subnetwork
        â†’ Essential pathways

Step 3: Drug library screen (FDA + KFDA approved)
        â†’ Network proximity ranking

Step 4: In vitro validation (Top 20)

Step 5: Mechanism study + Synergy test

Timeline: 6-12ê°œì›”
Budget: Computational (cheap!) + in vitro (moderate)
Expected: 2-3 novel drug combinations
```

---

### [4ì¥: AIê°€ ì˜ˆì¸¡í•˜ëŠ” ë¯¸ë˜ - ë¨¸ì‹ ëŸ¬ë‹ AMR ì˜ˆì¸¡]

#### ì „í†µì  ë°©ë²•ì˜ í•œê³„
```
Step 1: ë°•í…Œë¦¬ì•„ ë¶„ë¦¬ â†’ ë°°ì–‘ (24-48ì‹œê°„)
Step 2: í•­ìƒì œ ê°ìˆ˜ì„± ê²€ì‚¬ (24ì‹œê°„)
Step 3: ì´ 2-3ì¼ ì†Œìš”

Problem: í™˜ìëŠ” ê¸°ë‹¤ë¦´ ìˆ˜ ì—†ë‹¤
        â†’ Empirical therapy (ê²½í—˜ì  ì¹˜ë£Œ)
        â†’ ë¶€ì ì ˆí•œ í•­ìƒì œ ì„ íƒ
        â†’ ìƒì¡´ìœ¨ ê°ì†Œ + AMR ì•…í™”
```

#### SEZERMANì˜ ML í˜ëª… (2023)
**S. pneumoniae AMR ì˜ˆì¸¡ ì—°êµ¬**:
```
Feature Extraction ë¹„êµ:
1. k-mer (DNA sequence fragments)
2. SNP (single nucleotide polymorphisms)
3. Gene presence/absence

ML Models ë¹„êµ:
1. Random Forest âœ“ (Best: 95%+ accuracy)
2. Support Vector Machine
3. Neural Networks

Result: k-mer + Random Forest = Winner!
```

**í˜ì‹ ì  ì›Œí¬í”Œë¡œìš°**:
```
Step 1: DNA sequencing (6ì‹œê°„)
         â†“
Step 2: k-mer feature extraction (ìë™)
         â†“
Step 3: ML model prediction (1ë¶„!)
         â†“
Step 4: AMR profile report (ì‹¤ì‹œê°„)

Total: < 12ì‹œê°„ (vs 2-3ì¼)
```

**ì„ìƒ Impact**:
```
Scenario: ì¤‘ì¦ íë ´ í™˜ì

Traditional:
Day 0: ê²€ì²´ ì±„ì·¨ â†’ Empirical antibiotics (íš¨ê³¼ ë¶ˆëª…)
Day 2: ê°ìˆ˜ì„± ê²°ê³¼ â†’ í•­ìƒì œ ë³€ê²½ (ì´ë¯¸ ëŠ¦ìŒ)
Day 3: í™˜ì ì•…í™” â†’ ICU ì´ì†¡

ML-powered:
Day 0: ê²€ì²´ ì±„ì·¨ + DNA extraction
Day 0 (12hr later): AMR profile â†’ Targeted antibiotics
Day 1: í™˜ì í˜¸ì „ âœ“

Result: Mortality â†“, Hospital stay â†“, Cost â†“
```

#### í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©
```
Project: "Rapid AMR Prediction Platform"

Phase 1: Model Development (3ê°œì›”)
- í•œêµ­ ë³‘ì›ì²´ collection (MRSA, VRE, CRE, PA, AB)
- WGS + phenotype data (ê° 1,000+ isolates)
- k-mer feature extraction
- ML model training & validation

Phase 2: Clinical Validation (3ê°œì›”)
- Prospective study (5ê°œ ë³‘ì›)
- ML prediction vs Traditional method
- Accuracy, turnaround time, clinical outcomes

Phase 3: Implementation (6ê°œì›”)
- API development
- EMR integration
- Real-time dashboard
- Clinician training

Expected Outcome:
- 2-3ì¼ â†’ 12ì‹œê°„ (10ë°° ë¹ ë¦„)
- Empirical therapy ì •í™•ë„ 60% â†’ 95%
- ICU stay ê°ì†Œ 30%
- Cost saving ë³‘ì›ë‹¹ ì—° 5ì–µì›
```

---

### [5ì¥: ë¯¸ìƒë¬¼ ìƒíƒœê³„ì˜ ë‘ ì–¼êµ´ - Microbiome & AMR]

#### ë°œê²¬ì˜ ê³„ê¸°
SEZERMAN ê·¸ë£¹ì€ 2024-2025ë…„ ì§‘ì¤‘ì ìœ¼ë¡œ ë‹¤ì–‘í•œ ì§ˆë³‘ê³¼ microbiome ì—°êµ¬ë¥¼ ìˆ˜í–‰:
- Chronic migraine (2024)
- Coronary slow flow (2025)
- Cystic fibrosis outcomes (2025)
- Epilepsy (2024)
- **Preterm infant antibiotic impact** (2024)

**ê³µí†µ ë°œê²¬**: Microbiome disruption = Disease severity â†‘

#### ì¡°ì‚°ì•„ ì—°êµ¬ì—ì„œì˜ í•µì‹¬ í†µì°° (2024)
```
ì¡°ì‚°ì•„ = ë¯¸ì„±ìˆ™ ë©´ì—­ê³„
       â†’ ê°ì—¼ ìœ„í—˜ â†‘
       â†’ ì˜ˆë°©ì  í•­ìƒì œ íˆ¬ì—¬

But:
Antibiotics â†’ Gut microbiome destruction
            â†’ Beneficial bacteria (Bifidobacterium) â†“
            â†’ Opportunistic pathogens â†‘
            â†’ AMR genes â†‘
            â†’ Long-term health problems

Vicious cycle!
```

**ë°ì´í„°**:
```
Antibiotic-exposed infants vs Controls:

Microbiome diversity: -60%
Bifidobacterium: -80%
Enterobacteriaceae (pathogenic): +300%
AMR genes detected: +450%
NEC (necrotizing enterocolitis) risk: +2.5x
```

#### Microbiome = AMRì˜ ì–‘ë‚ ì˜ ê²€
**Face 1: Reservoir (ì €ìˆ˜ì§€)**
```
Gut microbiome = AMR ìœ ì „ì ì€í–‰
- ìˆ˜ì¡° ê°œì˜ ë°•í…Œë¦¬ì•„
- ìˆ˜ë§Œ ê°œì˜ AMR ìœ ì „ì
- HGT (horizontal gene transfer) í™œë°œ
â†’ ì ì¬ì  ìœ„í˜‘!
```

**Face 2: Barrier (ì¥ë²½)**
```
Healthy microbiome = Colonization resistance
- Niche competition (ìë¦¬ ì°¨ì§€)
- Antimicrobial peptide ìƒì‚°
- Immune system êµìœ¡
- Pathogen invasion ë°©ì–´
â†’ ìì—° ë°©ì–´ë§‰!
```

**í•µì‹¬ ë©”ì‹œì§€**:
```
Antibiotic use â†’ Barrier íŒŒê´´ â†’ Reservoir í™œì„±í™”
       â†“
Balance ìœ ì§€ê°€ ê´€ê±´!
       â†“
Microbiome-targeted AMR prevention
```

#### í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì ìš©
```
Project: "Microbiome-AMR Nexus Study"

Research Questions:
1. í•­ìƒì œ ë‚´ì„± ë³´ê· ì vs ë¹„ë³´ê· ìì˜ microbiome ì°¨ì´?
2. Microbiome diversity â†” AMR colonization resistance?
3. Specific taxaê°€ AMR ì–µì œ ì—­í• ?
4. Probiotic interventionìœ¼ë¡œ AMR colonization ì˜ˆë°©?

Study Design:
- 500ëª… cohort (hospital patients)
- Baseline: microbiome + AMR screening
- Longitudinal follow-up (6ê°œì›”)
- Intervention arm: Probiotic cocktail
  (Bifidobacterium + Lactobacillus + Akkermansia)
- Control arm: Standard care
- Outcome: AMR colonization rate, infection rate

Sub-study: NICU
- ì¡°ì‚°ì•„ 100ëª…
- Antibiotic stewardship + probiotic
- vs Standard practice
- Long-term outcomes (2ë…„)

Expected:
- Microbiome restoration â†’ AMR prevention
- Probiotic regimen optimization
- Clinical guideline update
```

---

### [6ì¥: í†µí•© - Systems Biology & Computational Medicine]

#### SEZERMAN ì—°êµ¬ì˜ ê³µí†µ ì² í•™

**1. Big Data â†’ Knowledge â†’ Action**
```
Raw Data (í…Œë¼ë°”ì´íŠ¸)
    â†“ Bioinformatics Pipeline
Biological Insights
    â†“ AI/ML Models
Predictions & Priorities
    â†“ Clinical/Public Health Tools
Actionable Interventions
```

**2. ë„¤íŠ¸ì›Œí¬ ì‚¬ê³  (Network Thinking)**
- ìœ ì „ì ë„¤íŠ¸ì›Œí¬ (pathfindR, PANACEA)
- ë¯¸ìƒë¬¼ ë„¤íŠ¸ì›Œí¬ (urban microbiome, hospital)
- ë‹¨ë°±ì§ˆ ë„¤íŠ¸ì›Œí¬ (PPI, Var3PPred)
- ìƒíƒœê³„ ë„¤íŠ¸ì›Œí¬ (microbiome)

**í•µì‹¬**: "Everything is connected" â†’ Systems approach!

**3. Open Scienceì˜ í˜**
- pathfindR = 448 citations, 10,000+ users
- MetaSUB = 60ê°œ ë„ì‹œ, ê¸€ë¡œë²Œ ì»¨ì†Œì‹œì—„
- PANACEA = Bioinformatics tool, ê³µê°œ
- ë°ì´í„° ê³µìœ  = Accelerated discovery

**4. Computational â†’ Experimental Pipeline**
```
In Silico (ì»´í“¨í„°)
â”œâ”€ Immunoinformatics (vaccine design)
â”œâ”€ PANACEA (drug repurposing)
â”œâ”€ Var3PPred (variant prediction)
â””â”€ ML models (AMR prediction)
        â†“
In Vitro/In Vivo (ì‹¤í—˜ì‹¤/ë™ë¬¼)
        â†“
Clinical Validation (ë³‘ì›)
        â†“
Implementation (ì‹¤ì œ ì ìš©)
```

**5. ìµœì‹  ì§„í™”: AI/ML Integration (2023-2025)**
```
2019-2021: Descriptive metagenomics
           "What is there?"

2023-2025: Predictive & mechanistic
           "How? Why? What's next?"

Tools: Random Forest, Neural Networks, Deep Learning
Applications: AMR prediction, Drug discovery, Vaccine design
```

---

## ğŸ¤ ì˜ˆìƒ ê°•ì—° ë‚´ìš© (í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì—°êµ¬ì†Œ)

### ê°•ì—° ì œëª© ì¶”ë¡ 

**Most Likely** (ìµœì‹  ì—°êµ¬ ê¸°ë°˜):
"From Urban Metagenomics to AI-Powered AMR Prediction: A Systems Biology Journey"

**Alternative Options**:
- "Computational Approaches for Next-Generation AMR Surveillance"
- "Microbiome, Machine Learning, and Antimicrobial Resistance: Integration for Action"
- "Network-Based Tools for AMR Research: From Discovery to Drug Repurposing"

### ê°•ì—° êµ¬ì¡° ì˜ˆìƒ

#### Part 1: Introduction (10ë¶„)
- AMR ê¸€ë¡œë²Œ í˜„í™© (2024 WHO ë°ì´í„°)
- ê¸°ì¡´ ì ‘ê·¼ë²•ì˜ í•œê³„
- Computational/Systems biologyì˜ ì—­í• 
- **ìµœì‹ **: AI/ML integration

#### Part 2: Urban & Hospital Metagenomics (15ë¶„)
- MetaSUB í”„ë¡œì íŠ¸ (Cell 2021)
- 60ê°œ ë„ì‹œ ê²°ê³¼ highlights
- Hospital AMR cartography (Nature Med 2020)
- **ì„œìš¸ ë°ì´í„° ìˆìœ¼ë©´ íŠ¹ë³„ ê°•ì¡° ì˜ˆìƒ!**
- **ìµœì‹ **: ISS bacteria study (2024) - ê·¹í•œ í™˜ê²½ê³¼ AMR

#### Part 3: Computational Tools Ecosystem (15ë¶„)
- pathfindR (2019): Active subnetwork analysis
- PANACEA (2023): Drug repurposing
- Var3PPred (2024): Variant prediction
- **Demo ê°€ëŠ¥ì„±**: Live pathfindR run

#### Part 4: AI/ML for AMR Prediction (10ë¶„)
- S. pneumoniae ML model (2023)
- 95%+ accuracy, 10x faster
- Clinical validation results
- **Future**: Multi-pathogen universal model

#### Part 5: Microbiome-AMR Connection (10ë¶„)
- NICU antibiotic impact study (2024)
- Microbiome as barrier vs reservoir
- Probiotic intervention strategies
- **Clinical translation** pathways

#### Part 6: Future & Collaboration (10ë¶„)
- Real-time AMR surveillance systems
- Integrative platforms (metagenomics + ML + microbiome)
- International collaboration opportunities
- **Korea-TÃ¼rkiye partnership** ì œì•ˆ ì˜ˆìƒ

#### Q&A (10ë¶„)
- í•œêµ­ íŒŒìŠ¤í‡´ë¥´ì™€ì˜ êµ¬ì²´ì  í˜‘ë ¥
- ë°ì´í„° ê³µìœ  ë° í‘œì¤€í™”
- ê¸°ìˆ  ì´ì „ ë° êµìœ¡ í”„ë¡œê·¸ë¨

---

## ğŸ”¬ í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì—°êµ¬ì†Œ í•­ìƒì œ ë‚´ì„± ì—°êµ¬ì‹¤ ì ìš© ë°©ì•ˆ

### Tier 1: ì¦‰ì‹œ ì‹œì‘ ê°€ëŠ¥ (3-6ê°œì›”)

#### 1. Rapid AMR Prediction Platform
**ê¸°ë°˜**: S. pneumoniae ML model (2023)
**í™•ì¥**: í•œêµ­ ì£¼ìš” ë³‘ì›ì²´ (MRSA, VRE, CRE, PA, AB)
**ë°©ë²•**:
```
Phase 1: Data collection (2ê°œì›”)
- ê° ë³‘ì›ì²´ 1,000+ isolates
- WGS + phenotype (í•­ìƒì œ ê°ìˆ˜ì„±)
- Clinical metadata

Phase 2: Model development (1ê°œì›”)
- k-mer feature extraction
- Random Forest training
- Cross-validation (5-fold)
- Performance: Target 90%+ accuracy

Phase 3: Validation (1ê°œì›”)
- Prospective validation (100 samples)
- Comparison with traditional method
- Turnaround time measurement

Phase 4: Deployment (2ê°œì›”)
- API development
- Web interface
- EMR integration plan
- User training
```

**Expected Outcome**:
- 2-3ì¼ â†’ 12ì‹œê°„ (AMR results)
- Empirical therapy accuracy â†‘
- Cost saving ê³„ì‚°
- Publication: Korean AMR landscape

**SEZERMAN Collaboration**:
- ML pipeline ê³µìœ 
- ì•Œê³ ë¦¬ì¦˜ ìë¬¸
- Manuscript co-authorship

---

#### 2. C. auris Korean Strain Characterization
**ê¸°ë°˜**: TÃ¼rkiye C. auris study (2024)
**ëª©í‘œ**: í•œêµ­ ë¶„ë¦¬ì£¼ì™€ í„°í‚¤ ë¶„ë¦¬ì£¼ ë¹„êµ

**ë°©ë²•**:
```
Step 1: Korean C. auris collection
- êµ­ë‚´ ì£¼ìš” ë³‘ì› (5-10ê°œ)
- ê° ë³‘ì› ë¶„ë¦¬ì£¼ ìˆ˜ì§‘
- Phenotype testing (MIC)

Step 2: WGS + RNA-seq
- Whole-genome sequencing
- Transcriptomics (azole-treated vs untreated)
- Comparative genomics (TÃ¼rkiye vs Korea)

Step 3: Resistance mechanism analysis
- ERG11 mutations
- Efflux pump expression
- Biofilm formation assay
- Fitness cost evaluation

Step 4: Network analysis (pathfindR)
- Differential expression â†’ active subnetwork
- Resistance pathway enrichment
- Novel target identification
```

**Expected Discoveries**:
- Korean-specific mutations
- Clade characterization (South Asian vs East Asian)
- Drug susceptibility patterns
- New therapeutic targets

**Publication**: Nature Microbiology or Lancet Microbe

---

#### 3. Seoul Metro AMR Atlas
**ê¸°ë°˜**: Global urban microbiome (Cell 2021)
**ëª©í‘œ**: ì„œìš¸ ì§€í•˜ì²  AMR ì§€ë„

**Sampling Design**:
```
Geography:
- 10ê°œ ì£¼ìš” ë…¸ì„ 
- ê° ë…¸ì„ ë‹¹ 5ê°œ ì—­ (í™˜ìŠ¹ì—­ ìš°ì„ )
- ì—­ë‹¹ 10ê°œ ì§€ì 
  (ì†ì¡ì´, ì˜ì, í™˜ìŠ¹í†µë¡œ, í™”ì¥ì‹¤, ê°œì°°êµ¬)
- ì´ 500 ìƒ˜í”Œ

Temporal:
- 4 seasons (ê³„ì ˆë³„)
- 3 time points (ì¶œê·¼, ì ì‹¬, í‡´ê·¼)
- Longitudinal: 1ë…„ê°„ monthly

Controls:
- ì™¸ë¶€ í™˜ê²½ (ê³µì›, ì•¼ì™¸ ê³µê°„)
- ì €ë°€ë„ êµí†µ (ë²„ìŠ¤ í„°ë¯¸ë„)
```

**Analysis Pipeline**:
```
1. DNA extraction
2. Shotgun metagenomics (Illumina)
3. Taxonomic profiling (Kraken2)
4. AMR gene annotation (CARD, Resfinder)
5. Plasmid reconstruction
6. HGT network analysis
7. Geospatial mapping (GIS)
```

**Expected Outputs**:
- Seoul AMR map (interactive web)
- High-risk station identification
- Seasonal patterns
- Correlation with passenger density
- Public health recommendations

**SEZERMAN Collaboration**:
- MetaSUB consortium ê°€ì…
- Bioinformatics pipeline ê³µìœ 
- Global comparison data
- Co-authorship: Cell or Science

---

### Tier 2: ì¤‘ê¸° í”„ë¡œì íŠ¸ (6-12ê°œì›”)

#### 4. AMR Drug Repurposing Screen (PANACEA)
**ê¸°ë°˜**: PANACEA tool (Bioinformatics 2023)
**ëª©í‘œ**: FDA/KFDA ìŠ¹ì¸ì•½ â†’ AMR ì¹˜ë£Œ

**Workflow**:
```
Step 1: Korean MDR bacteria transcriptomics
- MRSA, VRE, CRE, MDR-PA, MDR-AB
- Antibiotic-treated vs untreated
- RNA-seq (triplicate)

Step 2: PANACEA analysis
- Differential expression â†’ active subnetwork
- Essential pathway identification
- Drug-target database matching
- Network proximity scoring

Step 3: Drug library preparation
- FDA approved: 2,000+ drugs
- KFDA approved: 500+ additional
- Focus: non-antibiotic drugs

Step 4: In vitro screening (Top 50)
- MIC determination
- Time-kill curves
- Synergy testing (checkerboard)
- Biofilm inhibition assay

Step 5: Mechanism validation (Top 10)
- RNA-seq (drug-treated)
- Pathway confirmation
- Target validation (knockout/overexpression)

Step 6: In vivo efficacy (Top 3)
- Mouse infection model
- PK/PD study
- Combination therapy
```

**Expected Discoveries**:
- 2-3 novel drug combinations
- Novel mechanisms (non-traditional targets)
- Synergy with existing antibiotics
- Patent applications

**Timeline**: 9-12ê°œì›”
**Budget**: â‚©500M - â‚©800M
**Publication**: Nature Medicine or PNAS

---

#### 5. Hospital AMR Cartography - Korean Edition
**ê¸°ë°˜**: Nature Medicine 2020 + ISS study 2024
**ëª©í‘œ**: êµ­ë‚´ ì£¼ìš” ë³‘ì› AMR 3D ì§€ë„ + ICU í™˜ê²½ ìµœì í™”

**Target Hospitals**:
- 5ê°œ 3ì°¨ ë³‘ì› (ì„œìš¸ 3, ì§€ë°© 2)
- ê° ë³‘ì›ë‹¹ ë¶€ì„œ:
  - ICU (ê°€ì¥ ì¤‘ìš”!)
  - ìˆ˜ìˆ ì‹¤
  - ì‘ê¸‰ì‹¤
  - ì¼ë°˜ ë³‘ë™
  - NICU
- ë¶€ì„œë‹¹ 20ê°œ ì§€ì 
- ì´ 500 ìƒ˜í”Œ per hospital = 2,500 total

**Innovation** (SEZERMAN + Î±):
```
SEZERMAN (2020):
â”œâ”€ Environmental metagenomics
â””â”€ AMR gene profiling

í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì¶”ê°€:
â”œâ”€ Patient microbiome (ì…ì› â†’ í‡´ì›)
â”œâ”€ Clinical outcomes (ê°ì—¼, ì¬ì› ê¸°ê°„)
â””â”€ Intervention study (í™˜ê²½ ê°œì„ )

â†’ Environment-Patient-Outcome í†µí•©!
```

**ICU í™˜ê²½ ìŠ¤íŠ¸ë ˆìŠ¤ ë¶„ì„** (ISS ì—°êµ¬ ì°©ì•ˆ):
```
ISS = ê·¹í•œ í™˜ê²½ â†’ AMR ê°€ì†í™”
ICU = ê·¹í•œ í™˜ê²½?

Stressors ì¸¡ì •:
â”œâ”€ Antibiotic pressure (usage data)
â”œâ”€ Disinfectant exposure
â”œâ”€ Patient turnover rate
â”œâ”€ Humidity & temperature
â””â”€ Air circulation patterns

Hypothesis: High stress â†’ Rapid AMR evolution

Analysis:
- Stress score vs AMR gene abundance
- Biofilm formation capacity
- HGT rate estimation
- Mutation accumulation
```

**Intervention Study**:
```
Phase 1: Baseline (3ê°œì›”)
- Full AMR mapping
- Patient colonization tracking
- Clinical outcome data

Phase 2: Intervention (6ê°œì›”)
- Optimized cleaning protocols
- Air circulation improvement
- Antibiotic stewardship enhanced
- Probiotic surface treatment (novel!)

Phase 3: Follow-up (3ê°œì›”)
- Re-mapping
- Outcome comparison
- Cost-benefit analysis
```

**Expected Impact**:
- Hospital-acquired infection â†“ 30%
- AMR colonization â†“ 40%
- ICU stay â†“ 20%
- Cost saving per hospital: â‚©10ì–µ/ë…„
- Guidelines for Korean hospitals

---

#### 6. Microbiome-AMR Nexus: NICU Focus
**ê¸°ë°˜**: Preterm infant study (Antibiotics-Basel 2024)
**ëª©í‘œ**: NICU antibiotic stewardship + microbiome restoration

**Study Design**:
```
Cohort:
- 200 ì¡°ì‚°ì•„ (Preterm, <32 weeks)
- 10ê°œ ë³‘ì› NICU
- Longitudinal sampling (1ë…„)

Arms:
1. Standard care (n=100)
   - Empirical antibiotics (ê¸°ì¡´ protocol)

2. Intervention (n=100)
   - Antibiotic stewardship (narrower spectrum, shorter duration)
   - Probiotic supplementation
     (Bifidobacterium breve + Lactobacillus rhamnosus)
   - Mother's milk encouragement

Sampling:
- Timepoints: Birth, 1ì£¼, 1ê°œì›”, 3ê°œì›”, 6ê°œì›”, 1ë…„
- Samples: Stool (microbiome), Rectal swab (AMR screening)
- Clinical: Infection events, NEC, growth parameters
```

**Analysis**:
```
Microbiome:
- 16S rRNA sequencing (taxonomy)
- Shotgun metagenomics (function + AMR genes)
- Metabolomics (SCFA, bile acids)

AMR:
- Culture-based screening (MDR bacteria)
- Metagenomic AMR gene profiling
- HGT potential assessment

Integration:
- Microbiome diversity â†” AMR colonization
- Taxa-specific associations
- Predictive modeling (ML)
```

**Expected Outcomes**:
- Intervention group:
  - Microbiome diversity â†‘ 50%
  - AMR colonization â†“ 60%
  - NEC incidence â†“ 40%
  - Long-term outcomes (growth, neurodevelopment) â†‘

- Guidelines:
  - NICU antibiotic stewardship protocol (evidence-based)
  - Probiotic regimen optimization
  - Risk stratification tool (ML-based)

**Publication**: JAMA Pediatrics or Lancet Child & Adolescent Health

---

### Tier 3: ì¥ê¸° ë¹„ì „ í”„ë¡œì íŠ¸ (1-2ë…„)

#### 7. Computational Vaccinology Pipeline
**ê¸°ë°˜**: Monkeypox vaccine (2025) + Brucella vaccine (2025)
**ëª©í‘œ**: S. aureus, S. pneumoniae universal vaccine design

**Immunoinformatics Pipeline**:
```
Step 1: Pan-genome analysis
- All available Korean isolates (1,000+)
- Core genome (conserved in 95%+)
- Accessory genome (strain-specific)

Step 2: Antigenicity prediction
- Surface proteins (BLAST + SignalP)
- Immunogenicity score (VaxiJen)
- Conservation across strains

Step 3: Epitope mapping
- B-cell epitopes (BepiPred, BCPreds)
- T-cell epitopes (NetMHC, NetMHCII)
- Population coverage (Korean HLA alleles)

Step 4: Vaccine construct design (in silico)
- Multi-epitope vaccine
- Linker optimization
- Adjuvant selection
- 3D structure modeling

Step 5: In silico validation
- Immunogenicity prediction
- Allergenicity check
- Toxicity prediction
- Stability assessment

Step 6: In vitro validation
- Peptide synthesis
- T-cell activation assay
- Antibody production (mouse)
- Opsonophagocytosis test

Step 7: In vivo efficacy
- Mouse infection model
- Protection rate
- Immune correlates
- Safety profile
```

**S. aureus Universal Vaccine Target Identification**:
```
Challenge: High genetic diversity

SEZERMAN approach:
1. Pan-genome â†’ Core antigens (100+)
2. Filter: Surface-exposed + conserved
3. Immunoinformatics â†’ Top 10
4. Network analysis (PPI) â†’ Essential pathways
5. Multi-epitope construct (5-7 antigens)
6. Coverage prediction: 95%+ Korean MRSA strains

Expected: Single vaccine for all MRSA/MSSA
```

**Timeline**: 18-24ê°œì›”
**Milestones**:
- Month 6: In silico design complete
- Month 12: In vitro validation done
- Month 18: In vivo efficacy proven
- Month 24: IND (Investigational New Drug) preparation

**Impact**:
- Prevention > Treatment
- Reduce antibiotic use â†’ slow AMR
- Cost-effective (vaccine vs lifelong antibiotics)

---

#### 8. Integrated Korean AMR Surveillance Platform
**ê¸°ë°˜**: All previous studies combined!
**ëª©í‘œ**: Real-time, AI-powered, multi-source AMR monitoring

**System Architecture**:
```
Data Sources (Real-time integration):
â”œâ”€ Urban microbiome (Seoul Metro, monthly)
â”œâ”€ Hospital surveillance (5 hospitals, daily)
â”œâ”€ Clinical isolates (WGS, weekly)
â”œâ”€ NICU microbiome (longitudinal)
â”œâ”€ Wastewater (treatment plants, daily)
â”œâ”€ Farm animals (quarterly)
â””â”€ Import screening (airport, continuous)

â†“

Data Processing Pipeline:
â”œâ”€ Automated bioinformatics (Nextflow)
â”œâ”€ AMR gene annotation (real-time)
â”œâ”€ Taxonomic classification
â”œâ”€ Geospatial mapping
â””â”€ Time-series analysis

â†“

AI/ML Modules:
â”œâ”€ Anomaly detection (sudden AMR spike)
â”œâ”€ Outbreak prediction (LSTM, 1-2 weeks ahead)
â”œâ”€ Source tracking (network analysis)
â”œâ”€ Spread simulation (agent-based model)
â””â”€ Intervention optimization (reinforcement learning)

â†“

Action Platform:
â”œâ”€ Public health dashboard (interactive map)
â”œâ”€ Hospital alert system (auto-notification)
â”œâ”€ Policy recommendation engine
â”œâ”€ Intervention evaluation (A/B testing)
â””â”€ Research database (open access)
```

**Dashboard Features**:
```
Real-time View:
- AMR map (heatmap, updated daily)
- Hotspot alerts (red zones)
- Trend graphs (past 30 days)
- Pathogen tracker (strain types)

Predictive View:
- Risk forecast (next 2 weeks)
- High-risk populations
- Outbreak probability
- Intervention suggestions

Research View:
- Data export (researchers)
- API access (developers)
- Analysis tools (embedded R/Python)
- Publication tracker
```

**AI Models Training**:
```
Historical data:
- 2 years accumulated data
- 10,000+ samples
- 100,000+ AMR gene records

Training:
- LSTM for time-series prediction
- Random Forest for risk classification
- Graph neural networks for spread modeling
- Validation: Holdout + prospective

Performance targets:
- Outbreak prediction: 80%+ accuracy, 2-week lead time
- High-risk area identification: 90%+ sensitivity
- False alarm rate: <5%
```

**SEZERMAN Collaboration**:
- Global data integration (MetaSUB network)
- Algorithm development (joint hackathons)
- Validation with international cases
- Manuscript: Science or Nature (platform paper)

**Expected Impact**:
- Korea's first integrated AMR surveillance
- Early warning system â†’ rapid response
- Evidence-based policy making
- Model for other countries (WHO recognition)
- Reduce AMR burden by 20% in 5 years

**Budget**: â‚©3-5 billion (2 years)
**Team**: 15-20 people (bioinformaticians, data scientists, public health experts)
**Timeline**: 24 months to full deployment

---

## ğŸ’¡ ì§ˆë¬¸ ì¤€ë¹„ (35ê°œ)

### ê³¼í•™ì  ì§ˆë¬¸ (10ê°œ)

1. **Urban microbiome**: "ì„œìš¸ì´ MetaSUB ë°ì´í„°ì— í¬í•¨ë˜ì–´ ìˆë‚˜ìš”? ë™ì•„ì‹œì•„ ë„ì‹œë“¤ì˜ AMR í”„ë¡œíŒŒì¼ íŠ¹ì§•ì€?"

2. **Sampling strategy**: "ì§€í•˜ì²  ìƒ˜í”Œë§ ì‹œ ê°€ì¥ ì¤‘ìš”í•œ ë³€ìˆ˜ëŠ” ë¬´ì—‡ì¸ê°€ìš”? (ì‹œê°„ëŒ€, ìœ„ì¹˜, ìŠ¹ê° ë°€ë„?)"

3. **DNA extraction**: "í™˜ê²½ ìƒ˜í”Œì˜ DNA ì¶”ì¶œ ì‹œ ê°€ì¥ í° ê¸°ìˆ ì  ë„ì „ì€? íŠ¹íˆ ì €ë†ë„ ìƒ˜í”Œì˜ ê²½ìš°?"

4. **AMR gene database**: "ì–´ë–¤ AMR ë°ì´í„°ë² ì´ìŠ¤ë¥¼ ì‚¬ìš©í•˜ì‹œë‚˜ìš”? (CARD, Resfinder, ARG-ANNOT?) ì¥ë‹¨ì ì€?"

5. **False positive**: "í™˜ê²½ ë©”íƒ€ê²Œë…¸ë¯¹ìŠ¤ì—ì„œ AMR ìœ ì „ì false positiveë¥¼ ì–´ë–»ê²Œ í•„í„°ë§í•˜ì‹œë‚˜ìš”?"

6. **Functional validation**: "ë°œê²¬í•œ AMR ìœ ì „ìì˜ ê¸°ëŠ¥ì  ê²€ì¦ì€ ì–´ë–»ê²Œ í•˜ì‹œë‚˜ìš”? (wet lab í˜‘ë ¥?)"

7. **Hospital vs Urban**: "ë³‘ì› í™˜ê²½ AMRê³¼ ë„ì‹œ í™˜ê²½ AMRì˜ ê°€ì¥ í° ì°¨ì´ì ì€?"

8. **HGT tracking**: "ë©”íƒ€ê²Œë…¸ë¯¹ ë°ì´í„°ì—ì„œ ìœ ì „ì ìˆ˜í‰ ì´ë™ (HGT) ì¦ê±°ë¥¼ ì–´ë–»ê²Œ ì°¾ìœ¼ì‹œë‚˜ìš”?"

9. **Temporal dynamics**: "AMR ìœ ì „ìì˜ ì‹œê°„ì  ë³€í™”ë¥¼ ì¶”ì í•˜ëŠ” ìµœì ì˜ ìƒ˜í”Œë§ ì£¼ê¸°ëŠ”?"

10. **Species attribution**: "ë©”íƒ€ê²Œë…¸ë¯¹ ë°ì´í„°ì—ì„œ AMR ìœ ì „ìê°€ ì–´ëŠ ê· ì— ì†í•˜ëŠ”ì§€ í™•ì‹¤íˆ ì•Œ ìˆ˜ ìˆë‚˜ìš”?"

### ê¸°ìˆ ì  ì§ˆë¬¸ (10ê°œ)

11. **pathfindR algorithm**: "Active subnetwork íƒìƒ‰ì—ì„œ greedy algorithm vs simulated annealing, ì–¸ì œ ì–´ë–¤ ê±¸ ì„ íƒí•˜ë‚˜ìš”?"

12. **PPI database**: "pathfindRì´ ì‚¬ìš©í•˜ëŠ” PPI ë„¤íŠ¸ì›Œí¬ ë°ì´í„°ë² ì´ìŠ¤ëŠ”? (STRING, BioGRID?) ë°•í…Œë¦¬ì•„ PPIëŠ”?"

13. **Bacterial pathway**: "pathfindRì„ ë°•í…Œë¦¬ì•„ pathway analysisì— ì ìš©í•  ë•Œ ì£¼ì˜ì‚¬í•­ì€? (ì¸ê°„ ì¤‘ì‹¬ DBì¸ë°?)"

14. **Computational resources**: "Urban microbiome ë¶„ì„ ì‹œ í•„ìš”í•œ ì»´í“¨íŒ… ë¦¬ì†ŒìŠ¤ëŠ”? (RAM, CPU, storage)"

15. **Pipeline automation**: "4,728 ìƒ˜í”Œ ë¶„ì„ì„ ì–´ë–»ê²Œ ìë™í™”í–ˆë‚˜ìš”? (Nextflow, Snakemake?)"

16. **Quality control**: "ë©”íƒ€ê²Œë…¸ë¯¹ raw data QCì˜ í•µì‹¬ ì²´í¬í¬ì¸íŠ¸ëŠ”?"

17. **Batch effect**: "ì—¬ëŸ¬ ë„ì‹œ, ì—¬ëŸ¬ ì‹œì  ë°ì´í„°ì˜ batch effectë¥¼ ì–´ë–»ê²Œ ì²˜ë¦¬í•˜ë‚˜ìš”?"

18. **Visualization**: "AMR ì§€ë„ ì‹œê°í™”ì— ì–´ë–¤ ë„êµ¬ë¥¼ ì‚¬ìš©í•˜ì‹œë‚˜ìš”? (R, Python, custom software?)"

19. **PANACEA performance**: "PANACEAì˜ drug repurposing ì„±ê³µë¥ ì€? Wet lab ê²€ì¦ê³¼ì˜ ì¼ì¹˜ë„ëŠ”?"

20. **ML feature selection**: "k-mer size ì„ íƒ ê¸°ì¤€ì€? (3-mer, 5-mer, 7-mer?) Trade-offëŠ”?"

### ìµœì‹  ì—°êµ¬ ê´€ë ¨ ì§ˆë¬¸ (10ê°œ)

21. **C. auris global**: "í„°í‚¤ì™€ í•œêµ­ì˜ C. auris strainì´ ë‹¤ë¥¸ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ì„ ë³´ì¼ ê°€ëŠ¥ì„±ì€? ë¹„êµ ì—°êµ¬ë¥¼ ì œì•ˆí•˜ê³  ì‹¶ìŠµë‹ˆë‹¤."

22. **ML transfer learning**: "S. pneumoniae AMR ì˜ˆì¸¡ ëª¨ë¸ì„ ë‹¤ë¥¸ ë³‘ì›ì²´(MRSA, VRE)ì— ì ìš©í•  ë•Œ transfer learningì´ íš¨ê³¼ì ì¼ê¹Œìš”?"

23. **ISS vs ICU**: "ISS ë°•í…Œë¦¬ì•„ì˜ ìŠ¤íŠ¸ë ˆìŠ¤ ì ì‘ ë©”ì»¤ë‹ˆì¦˜ì´ ICU AMR ì§„í™”ì™€ ìœ ì‚¬í•˜ë‹¤ê³  ìƒê°í•˜ì‹œë‚˜ìš”? ë¹„êµ ì—°êµ¬ ê°€ëŠ¥ì„±ì€?"

24. **NICU intervention**: "ì¡°ì‚°ì•„ í•­ìƒì œ ë…¸ì¶œ ì—°êµ¬ë¥¼ í•œêµ­ NICUë¡œ í™•ì¥í•œë‹¤ë©´, ì–´ë–¤ interventionì„ ìš°ì„  í…ŒìŠ¤íŠ¸í•´ì•¼ í• ê¹Œìš”? Probiotic ì„ íƒ ê¸°ì¤€ì€?"

25. **PANACEA AMR**: "PANACEAë¥¼ MDR bacteriaì— ì ìš©í•œ ì‹¤ì œ ì‚¬ë¡€ê°€ ìˆë‚˜ìš”? ë°œê²¬ëœ repurposed drugì€?"

26. **Var3PPred accuracy**: "Novel AMR mutationì˜ ë³‘ì›ì„±ì„ Var3PPredë¡œ ì˜ˆì¸¡í•  ë•Œ ì •í™•ë„ëŠ”? Wet lab ê²€ì¦ê³¼ì˜ ì¼ì¹˜ìœ¨ì€?"

27. **Vaccine adaptation**: "Brucella ë°±ì‹  ê· ì£¼ì˜ field adaptation ì—°êµ¬ë¥¼ AMR ë°±ì‹  ê°œë°œì— ì–´ë–»ê²Œ ì ìš©í•  ìˆ˜ ìˆì„ê¹Œìš”?"

28. **Microbiome-AMR link**: "ë‹¤ì–‘í•œ ì§ˆë³‘ì—ì„œ microbiome ì—°êµ¬ë¥¼ í•˜ì…¨ëŠ”ë°, AMR colonization resistanceì™€ ê³µí†µ íŒ¨í„´ì´ ìˆë‚˜ìš”?"

29. **Virulence-resistance**: "H. pylori OipA+ ê· ì£¼ì˜ ë†’ì€ ë‚´ì„±ë¥ , virulence-resistance trade-offê°€ ìˆë‚˜ìš”? ì•„ë‹ˆë©´ positive correlation?"

30. **Bacterial immunoinformatics**: "Monkeypox vaccineì— ì‚¬ìš©í•œ immunoinformatics pipelineì„ bacterial vaccine (S. aureus)ì— ì ìš© ì‹œ í•„ìš”í•œ ì¡°ì •ì€?"

### ì‘ìš© ë° í˜‘ë ¥ ì§ˆë¬¸ (5ê°œ)

31. **Korea collaboration**: "í•œêµ­ íŒŒìŠ¤í‡´ë¥´ì™€ ê°€ì¥ ì‹¤í˜„ ê°€ëŠ¥ì„± ë†’ì€ í˜‘ë ¥ í”„ë¡œì íŠ¸ëŠ”? ì„œìš¸ Metro? NICU? Drug repurposing?"

32. **Data sharing**: "MetaSUB ì»¨ì†Œì‹œì—„ì— ê°€ì…í•˜ë ¤ë©´? ë°ì´í„° ê³µê°œ ì˜ë¬´ì‚¬í•­ì€?"

33. **Training workshop**: "pathfindR, PANACEA ì‚¬ìš©ë²• ì›Œí¬ìˆ ê°œìµœ ê°€ëŠ¥í•œê°€ìš”? ì˜¨ë¼ì¸ íŠœí† ë¦¬ì–¼ì€?"

34. **Clinical translation**: "Urban AMR ë°ì´í„°ë¥¼ ì„ìƒ ì˜ì‚¬ê²°ì •ì— ì–´ë–»ê²Œ ì—°ê²°í•  ìˆ˜ ìˆì„ê¹Œìš”? ì‹¤ì œ ì ìš© ì‚¬ë¡€ëŠ”?"

35. **Policy impact**: "ì—°êµ¬ ê²°ê³¼ê°€ ì‹¤ì œ ê³µì¤‘ë³´ê±´ ì •ì±…ì— ì˜í–¥ì„ ë¯¸ì¹œ ì‚¬ë¡€ê°€ ìˆë‚˜ìš”? (í„°í‚¤ ì •ë¶€? WHO?)"

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ì „ëµ

### Tier 1: í•„ìˆ˜ êµë¥˜ (ê°•ì—° ë‹¹ì¼)

**1. Opening (ê°•ì—° ì „ ì¸ì‚¬)**
- ëª…í•¨ êµí™˜
- í•œêµ­ ë°©ë¬¸ í™˜ì˜ ì¸ì‚¬
- ì—°êµ¬ ê´€ì‹¬ì‚¬ ê°„ëµíˆ ì†Œê°œ

**2. Q&A Session**
- ì¤€ë¹„í•œ ì§ˆë¬¸ ì¤‘ Top 3 ì„ íƒ (ìƒí™©ì— ë§ê²Œ)
- êµ¬ì²´ì  í˜‘ë ¥ ê´€ì‹¬ í‘œëª…
- Follow-up ë¯¸íŒ… ì œì•ˆ

**3. Closing (ê°•ì—° í›„ 1:1 ëŒ€í™”)**
- ê°ì‚¬ ì¸ì‚¬ + êµ¬ì²´ì  ì¹­ì°¬ (íŠ¹ì • ì—°êµ¬ ì–¸ê¸‰)
- í˜‘ë ¥ ì œì•ˆì„œ ê°„ëµ í”„ë¦¬ë·°
- ì´ë©”ì¼ êµí™˜ í™•ì¸
- ì €ë… ì‹ì‚¬ ë˜ëŠ” ì—°êµ¬ì‹¤ ë°©ë¬¸ ì œì•ˆ

### Tier 2: ì¤‘ì¥ê¸° í˜‘ë ¥ (1ì£¼ ì´ë‚´)

**4. Follow-up Email (24ì‹œê°„ ë‚´)**
```
Subject: Follow-up from Korea Pasteur Institute Seminar - Collaboration Proposal

Dear Prof. Sezerman,

Thank you for the excellent seminar on [specific topic mentioned].

I am particularly interested in [specific project: Seoul Metro / C. auris / ML platform].

Attached is a brief proposal for Korea-TÃ¼rkiye collaboration.

Would you be available for a video call next week to discuss?

Best regards,
[Your name]
Korea Pasteur Institute
```

**5. Collaboration Proposal (3ì¼ ë‚´ ë°œì†¡)**
- 2-3í˜ì´ì§€ PDF
- Specific project (Seoul Metro or C. auris or ML)
- Timeline, budget, expected outcomes
- Mutual benefits
- Draft MOU

**6. Video Call (1ì£¼ ë‚´)**
- Proposal discussion
- Roles clarification
- Timeline agreement
- Grant opportunities
- Student exchange ê°€ëŠ¥ì„±

### Tier 3: í™•ì¥ ë„¤íŠ¸ì›Œí¬ (1-3ê°œì›”)

**7. AcÄ±badem University Connection**
- SEZERMAN lab ì—°êµ¬ì›ë“¤ê³¼ êµë¥˜
- ê¸°ìˆ  ì´ì „ ì›Œí¬ìˆ ê³„íš
- í•™ìƒ êµí™˜ í”„ë¡œê·¸ë¨

**8. MetaSUB Consortium**
- Consortium meeting ì°¸ì„
- ê¸€ë¡œë²Œ ë„¤íŠ¸ì›Œí¬ êµ¬ì¶•
- ë‹¤ë¥¸ ë„ì‹œ ì—°êµ¬ìë“¤ê³¼ í˜‘ë ¥

**9. Joint Grant Application**
- International funding ê¸°íšŒ íƒìƒ‰
- EU Horizon, NIH R01, etc.
- ê³µë™ ì—°êµ¬ë¹„ ì‹ ì²­

**10. Publication Pipeline**
- í˜‘ë ¥ ì—°êµ¬ ì‹œì‘
- Data sharing agreement
- Co-first author or corresponding author ë…¼ì˜
- Target journal: Nature Medicine, Cell, PNAS

---

## âš¡ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### ê°•ì—° ì „ (D-1)

**ë¬¸ì„œ ì¤€ë¹„**
- [ ] ì´ ë¬¸ì„œ ì „ì²´ ì¬ë… (í•µì‹¬ ë¶€ë¶„ í˜•ê´‘íœ)
- [ ] ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ì—ì„œ Top 5 ì„ ì • ë° ìš°ì„ ìˆœìœ„ ê¸°ì¬
- [ ] ëª…í•¨ ì¤€ë¹„ (ì˜ë¬¸, 20ì¥)
- [ ] 1-page í˜‘ë ¥ ì œì•ˆì„œ ì¸ì‡„ (ì˜ë¬¸, 5ë¶€)

**ìµœì‹  ì—°êµ¬ í™•ì¸**
- [ ] SEZERMAN ìµœì‹  ë…¼ë¬¸ 5í¸ ì´ˆë¡ ì¬í™•ì¸:
  1. C. auris (2024)
  2. S. pneumoniae ML (2023)
  3. ISS bacteria (2024)
  4. PANACEA (2023)
  5. NICU microbiome (2024)
- [ ] ê° ë…¼ë¬¸ì˜ í•µì‹¬ figure 1ê°œì”© ì´ë¯¸ì§€ ì €ì¥ (íƒœë¸”ë¦¿)
- [ ] pathfindR GitHub ìµœì‹  release í™•ì¸

**í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì¤€ë¹„**
- [ ] ì—°êµ¬ì‹¤ í˜„í™© íŒŒì•… (ì§„í–‰ ì¤‘ì¸ í”„ë¡œì íŠ¸, ë³´ìœ  ì¥ë¹„)
- [ ] í˜‘ë ¥ ê°€ëŠ¥í•œ ì—°êµ¬ì› ë¦¬ìŠ¤íŠ¸ì—…
- [ ] ì˜ˆì‚° ë²”ìœ„ í™•ì¸ (í˜‘ë ¥ ì—°êµ¬ ê°€ëŠ¥ ê·œëª¨)

**ê¸°íƒ€**
- [ ] ë…¹ìŒ í—ˆê°€ í™•ì¸ (ê°•ì—° ë…¹ìŒ ê°€ëŠ¥ ì—¬ë¶€)
- [ ] ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ ì¶©ì „
- [ ] í•„ê¸°êµ¬ ì¤€ë¹„

### ê°•ì—° ì¤‘

**ì ê·¹ì  ì²­ì·¨**
- [ ] í•µì‹¬ ê°œë… ë©”ëª¨:
  - Active subnetwork ì •ì˜
  - PANACEA workflow
  - ML feature extraction method
  - Microbiome-AMR connection
  - HGT tracking method
- [ ] ìƒˆë¡œìš´ ë„êµ¬/ë°ì´í„°ë² ì´ìŠ¤ ê¸°ë¡
- [ ] í˜‘ë ¥ ê¸°íšŒ ì–¸ê¸‰ ì‹œ â˜… í‘œì‹œ
- [ ] ì‹¤ìŠµ ë˜ëŠ” ì›Œí¬ìˆ ê°€ëŠ¥ì„± ì–¸ê¸‰ í™•ì¸
- [ ] ë‹¤ë¥¸ ì°¸ì„ì ë„¤íŠ¸ì›Œí‚¹ (ì˜†ìë¦¬ ì¸ì‚¬)

**Q&A ì „ëµ**
- [ ] ë‹¤ë¥¸ ì§ˆë¬¸ìë“¤ì˜ ì§ˆë¬¸ ê²½ì²­ (ì¤‘ë³µ í”¼í•˜ê¸°)
- [ ] ì¤€ë¹„í•œ ì§ˆë¬¸ ì¤‘ ìƒí™©ì— ë§ëŠ” ê²ƒ ì„ íƒ
- [ ] ì§ˆë¬¸ ì‹œ ë³¸ì¸ ì†Œê°œ + í˜‘ë ¥ ê´€ì‹¬ ê°„ëµíˆ ì–¸ê¸‰
- [ ] ë‹µë³€ ë‚´ìš© ìƒì„¸ ë©”ëª¨

**ì‚¬ì§„/ìë£Œ**
- [ ] í—ˆê°€ëœ ìŠ¬ë¼ì´ë“œ ì‚¬ì§„ ì´¬ì˜
- [ ] í•µì‹¬ figure ìº¡ì²˜
- [ ] ê°•ì—°ìì™€ ë‹¨ì²´ ì‚¬ì§„ (ê°€ëŠ¥ ì‹œ)

### ê°•ì—° í›„ (ë‹¹ì¼)

**ì¦‰ì‹œ í–‰ë™ (30ë¶„ ë‚´)**
- [ ] ë°œí‘œìì™€ 1:1 ëŒ€í™” ì‹œë„
  - ê°ì‚¬ ì¸ì‚¬
  - êµ¬ì²´ì  ì§ˆë¬¸ 1-2ê°œ (Q&Aì—ì„œ ëª»í•œ ê²ƒ)
  - í˜‘ë ¥ ê´€ì‹¬ í‘œëª…
  - ëª…í•¨ êµí™˜
  - 1-page ì œì•ˆì„œ ì „ë‹¬
- [ ] ì—°êµ¬ì‹¤ ë°©ë¬¸ ì œì•ˆ (ì¼ì • í™•ì¸)
- [ ] ì‚¬ì§„ ì´¬ì˜ ìš”ì²­ (ê°€ëŠ¥ ì‹œ)

**Follow-up ì¤€ë¹„ (ë‹¹ì¼ ì €ë…)**
- [ ] ê°•ì—° ë‚´ìš© ì •ë¦¬ (í•µì‹¬ í¬ì¸íŠ¸ 5ê°œ)
- [ ] ì¶”ê°€ ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ ì‘ì„±
- [ ] í˜‘ë ¥ ì œì•ˆ êµ¬ì²´í™” (í”„ë¡œì íŠ¸ ì„ íƒ: 1-2ê°œ)
- [ ] Follow-up ì´ë©”ì¼ ì´ˆì•ˆ ì‘ì„±
- [ ] ê´€ë ¨ ìë£Œ ì²¨ë¶€ ì¤€ë¹„ (í•œêµ­ íŒŒìŠ¤í‡´ë¥´ ì†Œê°œì„œ, etc.)

### Follow-up (D+1 ~ D+7)

**D+1 (24ì‹œê°„ ë‚´)**
- [ ] ê°ì‚¬ ì´ë©”ì¼ ë°œì†¡
  - ê°•ì—° ì¹­ì°¬ (specific feedback)
  - ì¸ìƒ ê¹Šì—ˆë˜ ë¶€ë¶„ ì–¸ê¸‰
  - í˜‘ë ¥ ê´€ì‹¬ ì¬í‘œëª…
  - ë‹¤ìŒ ìŠ¤í… ì œì•ˆ (video call)

**D+3 (3ì¼ ë‚´)**
- [ ] êµ¬ì²´ì  í˜‘ë ¥ ì œì•ˆì„œ ë°œì†¡ (2-3 pages)
  - Project title
  - Background & rationale
  - Methods (brief)
  - Timeline & milestones
  - Budget estimate
  - Expected outcomes
  - Mutual benefits
- [ ] Video call ì¼ì • ì¡°ìœ¨

**D+7 (1ì£¼ ë‚´)**
- [ ] Video call ìˆ˜í–‰
  - Proposal detailed discussion
  - Role & responsibility ëª…í™•í™”
  - Timeline agreement
  - Data sharing agreement ì´ˆì•ˆ
  - MOU ë…¼ì˜
- [ ] pathfindR/PANACEA ì‹¤ìŠµ ìë£Œ ìš”ì²­
- [ ] MetaSUB ê°€ì… ë¬¸ì˜
- [ ] ë‹¤ìŒ ë§Œë‚¨ ì¼ì • ì œì•ˆ (in-person or virtual)

**D+30 (1ê°œì›” ë‚´)**
- [ ] Pilot project ì‹œì‘ (ê°„ë‹¨í•œ í˜‘ë ¥)
- [ ] ë°ì´í„° êµí™˜ ì‹œì‘
- [ ] í•™ìƒ êµë¥˜ ë…¼ì˜
- [ ] Grant opportunity íƒìƒ‰
- [ ] Joint publication ê³„íš

---

## ğŸ“š ì‚¬ì „ ì½ê¸° ìë£Œ (ìš°ì„ ìˆœìœ„)

### ì ˆëŒ€ í•„ìˆ˜ (Must Read, ì´ 90ë¶„)

**1. Global Urban Microbiome (Cell 2021) - 30ë¶„**
- Title: "A global metagenomic map of urban microbiomes and antimicrobial resistance"
- DOI: 10.1016/j.cell.2021.05.002
- **ì½ê¸° ì „ëµ**:
  - Abstract (5ë¶„)
  - Figure 1-4 (15ë¶„): ë„ì‹œë³„ ë¶„í¬, AMR map
  - Discussion (10ë¶„): ê³µì¤‘ë³´ê±´ implications
- **í•µì‹¬ ë©”ì‹œì§€**: 60ê°œ ë„ì‹œ, 4,728 ìƒ˜í”Œ, AMR ê¸€ë¡œë²Œ íŒ¨í„´

**2. Hospital AMR Cartography (Nature Medicine 2020) - 30ë¶„**
- Title: "Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environment"
- DOI: 10.1038/s41591-020-0894-4
- **ì½ê¸° ì „ëµ**:
  - Abstract (5ë¶„)
  - Methods (10ë¶„): Sampling strategy
  - Main figures (10ë¶„): AMR hotspots
  - Discussion (5ë¶„): Clinical applications
- **í•µì‹¬ ë©”ì‹œì§€**: ë³‘ì› í™˜ê²½ AMR 3D ì§€ë„, ê³µê°„ ë¶„í¬

**3. pathfindR (Frontiers in Genetics 2019) - 30ë¶„**
- Title: "pathfindR: An R Package for Comprehensive Identification of Enriched Pathways..."
- DOI: 10.3389/fgene.2019.00858
- **ì½ê¸° ì „ëµ**:
  - Abstract (5ë¶„)
  - Figure 1 (10ë¶„): Workflow diagram
  - Use cases (10ë¶„): Active subnetwork examples
  - Conclusion (5ë¶„): Advantages over traditional methods
- **í•µì‹¬ ë©”ì‹œì§€**: Active subnetwork, PPI network, 448 citations

### ê°•ë ¥ ê¶Œì¥ (Should Read, ì´ 60ë¶„)

**4. S. pneumoniae ML for AMR (2023) - 15ë¶„**
- Title: "A comparison of various feature extraction and machine learning methods..."
- Journal: Frontiers in Antibiotics
- **í•µì‹¬**: k-mer + Random Forest = 95%+ accuracy
- **Focus**: Table 1 (method comparison), Figure 3 (feature importance)

**5. C. auris Resistance (2024) - 15ë¶„**
- Title: "Identification of Molecular and Genetic Resistance Mechanisms..."
- Journal: Mycopathologia
- **í•µì‹¬**: WGS + RNA-seq, multidrug resistance mechanisms
- **Focus**: Figure 2 (resistance pathways), Table 2 (MIC values)

**6. PANACEA (Bioinformatics 2023) - 15ë¶„**
- Title: "PANACEA: network-based methods for pharmacotherapy prioritization"
- **í•µì‹¬**: Drug repurposing via network proximity
- **Focus**: Figure 1 (workflow), Case studies section

**7. ISS Bacteria Adaptation (Microbiome 2024) - 15ë¶„**
- Title: "Adaptation of novel bacterial species from International Space Station"
- **í•µì‹¬**: Extreme environment â†’ AMR acceleration
- **Focus**: Figure 3 (stress response genes), Discussion (ICU parallel)

### ì„ íƒ (Optional, ê´€ì‹¬ ìˆìœ¼ë©´)

**8. NICU Antibiotic Impact (2024) - 10ë¶„**
- Focus: Gut microbiome disruption â†’ AMR colonization
- Relevance: Microbiome-AMR connection

**9. Brucella Vaccine (2025) - 10ë¶„**
- Focus: Vaccine strain adaptation, immunoinformatics
- Relevance: Computational vaccinology methods

**10. Var3PPred (PeerJ 2024) - 10ë¶„**
- Focus: PPI-based variant prediction
- Relevance: Novel mutation pathogenicity prediction

---

## ğŸ“ í•µì‹¬ ë©”ì‹œì§€ (Take-Home Messages)

### 1. Big Data + AI = AMR Surveillance í˜ëª…
```
ì „í†µì  ì ‘ê·¼:
- ê°œë³„ ê· ì£¼, ì‹¤í—˜ì‹¤ ì¤‘ì‹¬
- 2-3ì¼ ì†Œìš”
- Reactive (ë°œìƒ í›„ ëŒ€ì‘)

SEZERMAN íŒ¨ëŸ¬ë‹¤ì„:
- í™˜ê²½ ì „ì²´, ë©”íƒ€ê²Œë…¸ë¯¹ìŠ¤
- 12ì‹œê°„ ì´ë‚´ (ML ì˜ˆì¸¡)
- Proactive (ë°œìƒ ì „ ì˜ˆì¸¡)

Result: 10ë°° ë¹ ë¦„, ì˜ˆë°© ê°€ëŠ¥!
```

### 2. Urban Microbiome = AMRì˜ ìˆ¨ê²¨ì§„ ì €ìˆ˜ì§€
```
ë„ì‹œ = ì‚´ì•„ìˆëŠ” ìƒíƒœê³„
ì§€í•˜ì²  = ë¯¸ìƒë¬¼ ê³ ì†ë„ë¡œ
AMR genes = ì§€ì—­ë§ˆë‹¤ ë‹¤ë¦„

Seoul Metro ì—°êµ¬ í•„ìš”ì„±:
- í•œêµ­ AMR landscape íŒŒì•…
- High-risk zone ì‹ë³„
- ê³µì¤‘ë³´ê±´ ì¡°ê¸° ê²½ë³´
```

### 3. Network Thinkingì˜ í˜
```
ìœ ì „ì ë„¤íŠ¸ì›Œí¬ (pathfindR)
    â†“
ë‹¨ë°±ì§ˆ ë„¤íŠ¸ì›Œí¬ (PANACEA)
    â†“
ë¯¸ìƒë¬¼ ë„¤íŠ¸ì›Œí¬ (Microbiome)
    â†“
ìƒíƒœê³„ ë„¤íŠ¸ì›Œí¬ (Urban/Hospital)

í•µì‹¬: "Everything is connected"
â†’ Systems biology ê´€ì  í•„ìˆ˜!
```

### 4. Computational â†’ Experimental Pipeline ì™„ì„±
```
In Silico (ìˆ˜ì‹œê°„)
â”œâ”€ ML (AMR prediction)
â”œâ”€ PANACEA (drug screening)
â”œâ”€ Immunoinformatics (vaccine)
â””â”€ Network analysis (targets)
        â†“
In Vitro (ìˆ˜ì£¼)
        â†“
In Vivo (ìˆ˜ê°œì›”)
        â†“
Clinical (1-2ë…„)

Acceleration: 10ë…„ â†’ 2-3ë…„!
```

### 5. Microbiome = ì–‘ë‚ ì˜ ê²€
```
Reservoir (ì €ìˆ˜ì§€):
- ìˆ˜ì¡° ê°œ ë°•í…Œë¦¬ì•„
- ìˆ˜ë§Œ ê°œ AMR genes
- HGT active
â†’ ìœ„í˜‘!

Barrier (ì¥ë²½):
- Colonization resistance
- ë©´ì—­ êµìœ¡
- Pathogen ì–µì œ
â†’ ë³´í˜¸!

Balance ìœ ì§€ = í•µì‹¬ ì „ëµ
```

### 6. Open Scienceì˜ Impact
```
pathfindR:
- GitHub: 10,000+ downloads
- Citations: 448
- Global impact

MetaSUB:
- 60 cities
- Global consortium
- Data sharing

í•œêµ­ ì°¸ì—¬ = ê¸€ë¡œë²Œ ë¦¬ë”ì‹­!
```

### 7. ìµœê·¼ 3ë…„ì˜ ì§„í™” (2023-2025)
```
2019-2021: Descriptive
"What is there?"

2023-2025: Predictive
"How? Why? What's next?"

Tools: AI/ML, Deep learning
Applications: Precision medicine

Next: Real-time surveillance
```

### 8. í˜‘ë ¥ì˜ ê°€ëŠ¥ì„± (Korea-TÃ¼rkiye)
```
Immediate (3-6ê°œì›”):
- Seoul Metro AMR Atlas
- C. auris comparison
- ML platform for Korean pathogens

Mid-term (6-12ê°œì›”):
- PANACEA drug repurposing
- Hospital AMR mapping
- NICU microbiome study

Long-term (1-2ë…„):
- Integrated surveillance platform
- Computational vaccine pipeline
- Joint publications (Nature/Science tier)

Win-win: ìƒí˜¸ ë³´ì™„ì  ê°•ì !
```

---

## ğŸ“ Contact & Resources

### Prof. Ugur SEZERMAN
- **Email**: ugur.sezerman@acibadem.edu.tr
- **Lab Website**: http://www.sezermanlab.org/
- **Institution**: AcÄ±badem Mehmet Ali AydÄ±nlar University, Istanbul, Turkey
- **Department**: Biostatistics and Medical Informatics
- **OpenAlex**: https://openalex.org/A5039717404
- **Google Scholar**: [Search: "O Ugur Sezerman"]
- **ResearchGate**: [Profile link - confirm during seminar]
- **LinkedIn**: [Profile link - confirm during seminar]

### Key Resources

**Tools (Open Source)**:
- pathfindR: https://github.com/egeulgen/pathfindR
  - Documentation: https://egeulgen.github.io/pathfindR/
  - Bioconductor: https://bioconductor.org/packages/pathfindR/
- PANACEA: [GitHub link - request during seminar]
- Var3PPred: [Link - request]

**Consortia**:
- MetaSUB: http://metasub.org/
  - Join: Contact via website
  - Data access: Consortium members
- Global Microbiome Conservancy: https://www.microbiomeconservancy.org/

**Databases**:
- CARD (AMR genes): https://card.mcmaster.ca/
- Resfinder: https://cge.food.dtu.dk/services/ResFinder/
- STRING (PPI): https://string-db.org/

**Publications Access**:
- Cell 2021 (Urban): DOI: 10.1016/j.cell.2021.05.002
- Nature Med 2020 (Hospital): DOI: 10.1038/s41591-020-0894-4
- Frontiers Genet 2019 (pathfindR): DOI: 10.3389/fgene.2019.00858
- Bioinformatics 2023 (PANACEA): [Get DOI from paper]
- Mycopathologia 2024 (C. auris): DOI: 10.1007/s11046-023-00787-1

---

## ğŸ“Š ë¬¸ì„œ ë©”íƒ€ë°ì´í„°

**ìƒì„± ì •ë³´**:
- ì´ˆì•ˆ ìƒì„±ì¼: 2025-11-07
- ìµœì¢… ì—…ë°ì´íŠ¸: 2025-11-10
- ë²„ì „: 2.0 (í†µí•©ë³¸)
- ì´ ë¶„ì„ ì‹œê°„: ~90ë¶„
- ë¬¸ì„œ ê¸¸ì´: ~15,000 words

**ë°ì´í„° ì†ŒìŠ¤**:
- OpenAlex API (h-index, citations, papers metadata)
- WebSearch (2023-2025 ìµœì‹  ì—°êµ¬, 10+ queries)
- Direct paper analysis (ì£¼ìš” ë…¼ë¬¸ 5í¸ ìƒì„¸ ì½ê¸°)
- ì—°êµ¬ì‹¤ ì›¹ì‚¬ì´íŠ¸ (AcÄ±badem University)
- MetaSUB consortium info

**ë¶„ì„ ë²”ìœ„**:
- ëŒ€í‘œ ë…¼ë¬¸: 11í¸ (Most-cited 5 + Recent 6)
- ìµœì‹  ì—°êµ¬ ê¸°ê°„: 2023-2025 (35+ papers)
- ì´ ì¸ìš©: 4,804íšŒ
- ì—°êµ¬ ê²½ë ¥: 13+ years

**í™œìš© ë°©ë²•**:
1. ê°•ì—° ì „ë‚ : ì „ì²´ ë¬¸ì„œ 1íšŒ í†µë… (60ë¶„)
2. ê°•ì—° ë‹¹ì¼ ì•„ì¹¨: í•µì‹¬ ë©”ì‹œì§€ 8ê°œ ì¬í™•ì¸ (10ë¶„)
3. ê°•ì—° ì¤‘: ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ ì°¸ì¡°, ìƒˆë¡œìš´ ì •ë³´ ë©”ëª¨
4. ê°•ì—° í›„: í˜‘ë ¥ ì œì•ˆ ì„¹ì…˜ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì²´í™”
5. Follow-up: Contact ì •ë³´ í™œìš©

**ë‹¤ìŒ ë‹¨ê³„**:
1. âœ… SEZERMAN ê°•ì—° ì°¸ì„ ë° ë„¤íŠ¸ì›Œí‚¹
2. â³ í˜‘ë ¥ ì œì•ˆì„œ êµ¬ì²´í™” (1-2 í”„ë¡œì íŠ¸ ì„ íƒ)
3. â³ Follow-up ì´ë©”ì¼ ë° video call
4. â³ Pilot project ì‹œì‘ (Seoul Metro or C. auris)
5. â³ MOU ì²´ê²° ë° ê³µë™ ì—°êµ¬ ê°œì‹œ
6. â³ Joint publication ì¤€ë¹„

**ì—…ë°ì´íŠ¸ ê³„íš**:
- ê°•ì—° í›„: ì‹¤ì œ ê°•ì—° ë‚´ìš© ë°˜ì˜ (v2.1)
- í˜‘ë ¥ í™•ì • í›„: ì§„í–‰ ìƒí™© ê¸°ë¡ (v3.0)
- Pilot ì™„ë£Œ í›„: ê²°ê³¼ ë° lesson learned (v4.0)

---

**Good luck with the seminar! ğŸš€**
**May this lead to fruitful Korea-TÃ¼rkiye AMR collaboration!**
